ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Shingrix, Pulver und Suspension zur Herstellung einer Injektionssuspension - 10 + 10
67987002 GlaxoSmithKline AG
Shingrix, Pulver und Suspension zur Herstellung einer Injektionssuspension07.10.2021
  07.10.2021
Zoster, Purified Antigen (J07BK03) 
WHO-DDD06.10.2026
08.08.10 + 10
08.08. 
B  
No 
IP 
PR  
k.A.PR
  
7680679870024Impfstoffe
  
Composition
Pulver: glycoproteini E viri Varicellae Zoster antigenum 50 µg, saccharum, polysorbatum 80, natrii dihydrogenophosphas dihydricus, dikalii phosphas anhydricus, pro praeparatione. Solvens: Adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. Suspensio reconstituta: glycoproteini E viri Varicellae Zoster antigenum 50 µg, saccharum, polysorbatum 80, Adeps A 3-O-desacyl-4’-monophosphorylatus, Quillajae saponariae Molina saponinum purificatum, 1,2-dioleoyl-sn-glycero-3-phosphocholinum, cholesterolum, natrii chloridum, natrii dihydrogenophosphas anhydricus, dikalii phosphas anhydricus, dinatrii phosphas, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.77 mg, kalium 0.18 mg.
Packungsbestandteile
 
Source
Data was imported : 04.12.2021 Swissmedic Registration : Sequence : Product name : Registration owner: : Product group : Index Therapeuticus (BSV) : Medication Code : Date of registration : Valid until : Package number : Show package size : Commercial Form/Unit : Swissmedic categorie. : Active Agents : Composition :
 
2024 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home